Molecure signs deal with Ocean Biomedical, cleans up discovery pipeline
Oct. 16, 2024
Molecure SA has signed an exclusive licensing agreement with Ocean Biomedical Inc. for the development and commercialization of a selective YKL-40 inhibitor program, including the lead molecule OAT-3912.